HOUSTON--(BUSINESS WIRE)--April 24, 2006--Power3 Medical Products, Inc. (PWRM.PK), a leading proteomics company that develops and commercializes early detection diagnostic tests for cancer and neurodegenerative diseases, today said it has filed a provisional application with the U.S. Patent Office for a test, a drug target and therapeutic design specifications with the potential to overcome resistance to the leading drug used to treat Chronic Myelogenous Leukemia (CML).
